Results of a new study may offer regulators enough evidence to allow the psychedelic, also known as Ecstasy, to be considered for use as a PTSD treatment.
https://siii-clinical.com/wp-content/uploads/2021/09/Untitled-1.png00https://siii-clinical.com/wp-content/uploads/2021/09/Untitled-1.png2023-09-14 15:28:482023-09-14 15:28:48MDMA Therapy for PTSD Inches Closer to U.S. Approval
From research laboratories to clinical settings, SIII integrates the technologies, resources, and expertise our customers need to rise to the next opportunity. SIII is dedicated to exploring and researching the processes and scientific mechanisms underlying the world we live in.